Literature DB >> 30186001

Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid.

Jessica Auyeung1, Monica Lee2.   

Abstract

Entities:  

Year:  2018        PMID： 30186001      PMCID： PMC6118827     

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  19 in total

Review 1.  Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Med Clin North Am       Date:  2010-07       Impact factor: 5.456

2.  Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  L Valeyrie-Allanore; P Wolkenstein; L Brochard; N Ortonne; B Maître; J Revuz; M Bagot; J C Roujeau
Journal:  Br J Dermatol       Date:  2010-10       Impact factor: 9.302

Review 3.  Ciprofloxacin-induced toxic epidermal necrolysis: a case report.

Authors:  C A Livasy; A M Kaplan
Journal:  Dermatology       Date:  1997       Impact factor: 5.366

4.  Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.

Authors:  Gokhan Okan; Serpil Yaylaci; Onder Peker; Sabahattin Kaymakoglu; Murat Saruc
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

5.  U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016.

Authors:  D Creamer; S A Walsh; P Dziewulski; L S Exton; H Y Lee; J K G Dart; J Setterfield; C B Bunker; M R Ardern-Jones; K M T Watson; G A E Wong; M Philippidou; A Vercueil; R V Martin; G Williams; M Shah; D Brown; P Williams; M F Mohd Mustapa; C H Smith
Journal:  Br J Dermatol       Date:  2016-06       Impact factor: 9.302

6.  Stevens-Johnson syndrome presumably induced by ciprofloxacin.

Authors:  A Win; M L Evers; H Chmel
Journal:  Int J Dermatol       Date:  1994-07       Impact factor: 2.736

7.  Ciprofloxacin-induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus.

Authors:  M Jongen-Lavrencic; P M Schneeberger; J G van der Hoeven
Journal:  Infection       Date:  2003-12       Impact factor: 3.553

8.  Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.

Authors:  Mark G Kirchhof; Monica A Miliszewski; Sheena Sikora; Anthony Papp; Jan P Dutz
Journal:  J Am Acad Dermatol       Date:  2014-07-30       Impact factor: 11.527

9.  Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN).

Authors:  G Sakellariou; P Koukoudis; J Karpouzas; E Alexopoulos; D Papadopoulou; F Chrisomalis; N Skenteris; D Tsakaris; M Papadimitriou
Journal:  Int J Artif Organs       Date:  1991-10       Impact factor: 1.595

10.  Toxic epidermal necrolysis and agranulocytosis: rare adverse effects of ciprofloxacin.

Authors:  Gatha M Upadya; K Ruxana
Journal:  Indian J Med Sci       Date:  2009-10
View more
  3 in total

1.  Erratum: Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid: Correction.

Authors: 
Journal:  Can J Hosp Pharm       Date:  2018-10-31

Review 2.  Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.

Authors:  Audrey Jacobsen; Bayanne Olabi; Annie Langley; Jennifer Beecker; Eric Mutter; Amanda Shelley; Brandon Worley; Timothy Ramsay; Arturo Saavedra; Roses Parker; Fiona Stewart; Jordi Pardo Pardo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-11

3.  Behcet's disease: Diagnosed as isolated recurrent oral aphthae; a case report.

Authors:  Maysoun Kudsi; Naram Khalayli; Amr Allahham
Journal:  Ann Med Surg (Lond)       Date:  2022-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.